TVTX
Travere Therapeutics, Inc.Healthcare · $5.5B market cap
Verdict
We can't put a fair value on TVTX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow TVTX
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds TVTX. In Q2 2026, 1 opened a position. Who we track
Moves in Q2 2026
New position: Polen Capital Management
Insider activity
Since Sep 2, 2026: no open-market purchases, 5 sales worth $1.4M and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Meckler Jeffrey A
director · 2026-09-10
Sold
$211K
Meckler Jeffrey A
director · 2026-09-10
Sold
$944K
Meckler Jeffrey A
director · 2026-09-10
Sold
$79K
Meckler Jeffrey A
director · 2026-09-10
Sold
$111K
Cline Christopher R.
CHIEF FINANCIAL OFFICER · 2026-09-02
Sold
$43K
Other filings
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works